Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Company News

GSK, Pfizer JV allows both pharmas to focus on innovation

December 21, 2018 7:25 PM UTC

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) took the first step toward splitting up the pharma's consumer healthcare and innovative R&D businesses by agreeing to form a consumer healthcare joint venture with Pfizer Inc. (NYSE:PFE). The British pharma intends to separate from the JV within three years of the close of the deal and list the consumer healthcare business on a U.K. equity market, allowing both companies to focus on their innovative medicines businesses.

The all-stock transaction will result in GSK owning 68% of the JV -- which will operate under the GSK consumer healthcare brand -- while Pfizer will own the remaining 32%. GSK said the combined entity had 2017 global sales of about $12.7 billion. GSK will have the sole right to determine when to separate and list the JV for the first five years following the closing of the deal. Both pharmas have the right to either disperse their equity interest to existing shareholders or sell it through an IPO...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Glaxosmithkline plc

Pfizer Inc.